The Sustainable Development Goals (SDGs), adopted at the UN
Sustainable Development Summit held in September 2015, comprise 17
goals and 169 targets to create a future where no one is left behind
and are global efforts to be accomplished by 2030.
In response to the diverse and changing social expectations and
demands, the Sumitomo Pharma Group has identified Material Issues
based on its belief that it is important to realize both
contribution to social sustainability and its own sustained growth
through the creation of value that only it can deliver by utilizing
the Group’s capital (strengths) and also the development goals
of the SDGs.
Going forward, the Sumitomo Pharma Group will continue to contribute
to the realization of a sustainable society by addressing the issues
facing society.
SDGs to which the Sumitomo Pharma Group contributes
While concentrating our efforts primarily on Goal 3, which is
directly related to Sumitomo Pharma’s Mission and where we can
best utilize our strengths, we are also actively working on Goal 8,
10, 12, 13, 16, and 17.
The Sumitomo Pharma Group’s Top Priority: Sustainable
Development Goals and Main Targets
Goals
Targets
Initiatives of the pharmaceutical business (psychiatry
& neurology, oncology etc.), the Regenerative
Medicine/Cell Therapy Business and the Frontier Business
(3.4)
Addressing product safety and adverse reactions (3.4)
Providing and collecting product information (healthcare
professionals) (3.4)
Initiatives to improve medicine-related literacy (3.4)
Operation of information websites for healthcare
professionals and for patients and general public (3.4)
Initiatives aimed at appropriate use of antibiotics and
countermeasures to antimicrobial resistance (AMR) (3.3)
Participation in GHIT Fund to develop medicines for
malaria and other infectious diseases (3.3)
Health and productivity management (welfare of employees
and promoting mental health) (3.8)
Promotion of Work Style Innovation aimed at more
sophisticated work styles and a virtuous cycle in
work-life balance (8.5)
CSR procurement (8.7)
Supporting active participation by people with
disabilities through appropriate placement (8.5)
Health and productivity management (welfare of employees
and promoting mental health) (8.5)
Supporting active participation by people with
disabilities through appropriate placement (10.2)
Supporting independence and social reintegration of people
with disabilities (10.2)
CSR procurement (10.2, 10.3)
Support for developing countries through company
cafeterias (10.2)
Maintenance and improvement of recycling rate for waste
(12.4, 12.5)
Risk mitigation of environmental accidents (12.4)
Initiatives to reduce environmental impact throughout
products' lifecycles (12.4, 12.5)
Stable product supply and quality assurance (12.6)
Risk mitigation of natural disasters (12.6)
Responding to TCFD (13.1)
Implementing planned investment in carbon neutral
equipment(13.1)
Replace company vehicles with hybrid or electric vehicles
(13.1)
Collaboration with Sumitomo Chemical group companies and
Sumitomo Pharma's subsidiaries (SBT), and collaboration
with supply chains (Scope3) (13.1)
Effective use of energy via “Decokatsu” initiative and
other energy saving actions (13.1)
Utilization of solar power generating systems (13.1)
Purchase of renewable energy-derived electricity (13.1)
Purchase of Non-Fossil Certificates (13.1)
Initiatives to reduce environmental impact throughout
products' lifecycles (13.1)
Enhancement of corporate governance (16.5)
Pursuing compliance (16.1, 16.5)
CSR procurement (16.1, 16.2, 16.5)
Partnership activities for sustainable
development（17.7）
Industry-academia-government collaborative R&D
(academic institutions, startup companies, AMED, GHIT
Fund, etc.)
JPMA (Japan Pharmaceutical Manufacturers Association)
CDP
TABLE FOR TWO, etc.
